Inhibikase Therapeutics I...

2.49
0.16 (6.87%)
At close: Feb 06, 2025, 1:55 PM
undefined%
Bid 2.48
Market Cap 172.71M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -3.12
PE Ratio (ttm) -0.8
Forward PE n/a
Analyst Buy
Ask 2.5
Volume 151,563
Avg. Volume (20D) 314,836
Open 2.35
Previous Close 2.33
Day's Range 2.29 - 2.53
52-Week Range 1.12 - 4.20
Beta undefined

About IKT

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic const...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 23, 2020
Employees 8
Stock Exchange NASDAQ
Ticker Symbol IKT

Analyst Forecast

According to 2 analyst ratings, the average rating for IKT stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 161.04% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 months ago
-13.14%
Inhibikase Therapeutics shares are trading lower. ... Unlock content with Pro Subscription
2 months ago
+3.6%
Inhibikase Therapeutics shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced an $8 price target.